Targeted sequencing of plasmacytoid urothelial carcinoma reveals frequent TERT promoter mutations

Doreen N. Palsgrove, Diana Taheri, Simeon U. Springer, Morgan Cowan, Gunes Guner, Maria A. Mendoza Rodriguez, Maria Del Carmen Rodriguez Pena, Yuxuan Wang, Isaac Kinde, Bernardo F.P. Ricardo, Isabela Cunha, Kazutoshi Fujita, Dilek Ertoy, Kenneth W. Kinzler, Trinity J. Bivalacqua, Nickolas Papadopoulos, Bert Vogelstein, George J. Netto

Research output: Contribution to journalArticle

7 Scopus citations

Abstract

Activating mutations in the promoter of the telomerase reverse transcriptase (TERT) gene are the most common genetic alterations in urothelial carcinoma (UC) of the bladder and upper urinary tract. Although the cadherin 1 (CDH1) gene is commonly mutated in the clinically aggressive plasmacytoid variant of urothelial carcinoma (PUC), little is known about their TERT promoter mutation status. A retrospective search of our archives for PUC and UC with plasmacytoid and/or signet ring cell features (2007-2014) was performed. Ten specimens from 10 patients had archived material available for DNA analysis and were included in the study. Intratumoral areas of nonplasmacytoid histology were also evaluated when present. Samples were analyzed for TERT promoter mutations with Safe-SeqS, a sequencing error-reduction technology, and sequenced using a targeted panel of the 10 most commonly mutated genes in bladder cancer on the Illumina MiSeq platform. TERT promoter mutations were detected in specimens with pure and focal plasmacytoid features (6/10). Similar to conventional UC, the predominant mutation identified was g.1295228C>T. In heterogeneous tumors with focal variant histology, concordant mutations were found in plasmacytoid and corresponding conventional, glandular, or sarcomatoid areas. Co-occurring mutations in tumor protein p53 (TP53, 2 cases) and kirsten rat sarcoma (KRAS) viral proto-oncogene (1 case) were also detected. TERT promoter mutations are frequently present in PUC, which provides further evidence that TERT promoter mutations are common events in bladder cancer, regardless of histologic subtype, and supports their inclusion in any liquid biopsy assay for bladder cancer.

Original languageEnglish (US)
Pages (from-to)1-9
Number of pages9
JournalHuman Pathology
Volume85
DOIs
StatePublished - Mar 2019
Externally publishedYes

Keywords

  • Mutation
  • Plasmacytoid
  • PUC
  • Telomerase reverse transcriptase
  • TERT
  • Urothelial carcinoma

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Fingerprint Dive into the research topics of 'Targeted sequencing of plasmacytoid urothelial carcinoma reveals frequent TERT promoter mutations'. Together they form a unique fingerprint.

  • Cite this

    Palsgrove, D. N., Taheri, D., Springer, S. U., Cowan, M., Guner, G., Mendoza Rodriguez, M. A., Rodriguez Pena, M. D. C., Wang, Y., Kinde, I., Ricardo, B. F. P., Cunha, I., Fujita, K., Ertoy, D., Kinzler, K. W., Bivalacqua, T. J., Papadopoulos, N., Vogelstein, B., & Netto, G. J. (2019). Targeted sequencing of plasmacytoid urothelial carcinoma reveals frequent TERT promoter mutations. Human Pathology, 85, 1-9. https://doi.org/10.1016/j.humpath.2018.10.033